Home > Publications database > Biologic and behavioral associations of estrogen receptor alpha positivity in head and neck squamous cell carcinoma. > print

001     169985
005     20240229133702.0
024 7 _ |a 10.1016/j.oraloncology.2021.105461
|2 doi
024 7 _ |a pmid:34304004
|2 pmid
024 7 _ |a 1368-8375
|2 ISSN
024 7 _ |a 1744-7895
|2 ISSN
024 7 _ |a 1878-0601
|2 ISSN
024 7 _ |a 1879-0593
|2 ISSN
024 7 _ |a altmetric:110464387
|2 altmetric
037 _ _ |a DKFZ-2021-01685
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Drake, Virginia
|b 0
245 _ _ |a Biologic and behavioral associations of estrogen receptor alpha positivity in head and neck squamous cell carcinoma.
260 _ _ |a Amsterdam [u.a.]
|c 2021
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1642171554_15951
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2021 Oct;121:105461
520 _ _ |a Tumor HPV status is an established independent prognostic marker for oropharynx cancer (OPC). Recent studies have reported that tumor estrogen receptor alpha (ERα) positivity is also associated with prognosis independent of HPV. Little is known about the biologic and behavioral predictors of ERα positivity in head and neck squamous cell cancer (HNSCC). We therefore explored this in a multicenter prospective cohort study.Participants with HNSCC completed a survey and provided a blood sample. Tumor samples were tested for ERα using immunohistochemistry. ERα positivity was defined as ≥1%, standardized by the American Society of Clinical Oncology/College of American Pathologists in breast cancer. Characteristics were compared with χ2 and Fisher's exact test. Odds ratios (OR) were calculated using logistic regression.Of 318 patients with HNSCC, one third had ERα positive tumors (36.2%, n = 115). Odds of ERα expression were significantly increased in those with HPV-positive tumors (OR = 27.5, 95% confidence interval[CI] 12.1-62), smaller tumors (≤T2, OR = 3.6, 95% CI 1.9-7.1), male sex (OR = 2.0, 95% CI 1.1-3.6), overweight/obesity (BMI ≥ 25, OR = 1.9, 95% CI 1.1-3.3), and those married/living with a partner (OR = 1.7, 95% CI 1.0-3.0). In a multivariate model, HPV-positivity (aOR = 27.5, 95% CI 11.4-66) and small tumor size (≤T2, aOR = 2.2, 95% CI 1.0-4.8) remained independently associated with ERα status. When restricted to OPC (n = 180), tumor HPV status (aOR = 17.1, 95% CI 2.1-137) and small tumor size (≤T2, aOR = 4.0 95% CI 1.4-11.3) remained independently associated with ERα expression.Tumor HPV status and small tumor size are independently associated with ERα expression in HNSCC.
536 _ _ |a 316 - Infektionen, Entzündung und Krebs (POF4-316)
|0 G:(DE-HGF)POF4-316
|c POF4-316
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a Estrogen receptor alpha
|2 Other
650 _ 7 |a Head and neck neoplasms
|2 Other
650 _ 7 |a Oropharyngeal neoplasms
|2 Other
650 _ 7 |a Papillomaviridae
|2 Other
650 _ 7 |a Tumor biomarkers
|2 Other
700 1 _ |a Bigelow, Elaine
|b 1
700 1 _ |a Fakhry, Carole
|b 2
700 1 _ |a Windon, Melina
|b 3
700 1 _ |a Rooper, Lisa M
|b 4
700 1 _ |a Ha, Patrick
|b 5
700 1 _ |a Miles, Brett
|b 6
700 1 _ |a Gourin, Christine
|b 7
700 1 _ |a Mandal, Rajarsi
|b 8
700 1 _ |a Mydlarz, Wojciech
|b 9
700 1 _ |a London, Nyall
|b 10
700 1 _ |a Vosler, Peter S
|b 11
700 1 _ |a Yavvari, Siddhartha
|b 12
700 1 _ |a Troy, Tanya
|b 13
700 1 _ |a Waterboer, Tim
|0 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30
|b 14
|u dkfz
700 1 _ |a Eisele, David W
|b 15
700 1 _ |a D'Souza, Gypsyamber
|b 16
773 _ _ |a 10.1016/j.oraloncology.2021.105461
|g Vol. 121, p. 105461 -
|0 PERI:(DE-600)2011971-9
|p 105461
|t Oral oncology
|v 121
|y 2021
|x 1368-8375
909 C O |p VDB
|o oai:inrepo02.dkfz.de:169985
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-316
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Infektionen, Entzündung und Krebs
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2021-01-27
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2021-01-27
920 1 _ |0 I:(DE-He78)F020-20160331
|k F020
|l Infektionen und Krebs-Epidemiologie
|x 0
920 1 _ |0 I:(DE-He78)F022-20160331
|k F022
|l Infektionen und Krebs-Epidemiologie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F020-20160331
980 _ _ |a I:(DE-He78)F022-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21